Goldman Sachs Group set a CHF 102 price objective on Novartis (VTX:NOVN) in a research report report published on Thursday, Borsen Zeitung reports. The firm currently has a buy rating on the stock.
Several other equities analysts have also issued reports on the stock. HSBC set a €101.00 ($117.44) target price on shares of Grenke and gave the company a buy rating in a report on Thursday, April 25th. Kepler Capital Markets set a €160.00 ($186.05) target price on shares of Pfeiffer Vacuum Technology and gave the company a buy rating in a report on Tuesday, May 21st. Morgan Stanley boosted their target price on shares of Intact Financial from C$125.00 to C$128.00 in a report on Thursday, May 30th. UBS Group reiterated a neutral rating on shares of CAIXABANK/ADR in a report on Thursday. Finally, Jefferies Financial Group upped their price objective on shares of Nice to $166.00 and gave the company a buy rating in a report on Thursday, May 16th. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the company. The company currently has an average rating of Hold and an average price target of CHF 88.64.
Novartis has a fifty-two week low of CHF 72.45 and a fifty-two week high of CHF 88.30.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
Featured Story: What is net income?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.